Market Closed -
Nasdaq
04:00:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
12.11
USD
|
-0.41%
|
|
-9.96%
|
-44.40%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
15.26
|
64.29
|
429.5
|
1,176
|
1,145
|
772.9
|
-
|
-
|
Enterprise Value (EV)
1 |
-7.262
|
64.29
|
232.5
|
755.7
|
688.2
|
310.6
|
147.7
|
341.2
|
P/E ratio
|
-0.36
x
|
-0.53
x
|
-2.96
x
|
-7.21
x
|
-4.1
x
|
-3.27
x
|
-3.09
x
|
-4.33
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.42
x
|
61.2
x
|
145
x
|
663
x
|
3,648
x
|
2,087
x
|
2,342
x
|
6.07
x
|
EV / Revenue
|
-1.63
x
|
61.2
x
|
78.5
x
|
426
x
|
2,192
x
|
838
x
|
448
x
|
2.68
x
|
EV / EBITDA
|
-
|
-
|
-3.57
x
|
-5.64
x
|
-3.68
x
|
-1.59
x
|
-0.6
x
|
-1.3
x
|
EV / FCF
|
-
|
-2.16
x
|
-4.26
x
|
-7.99
x
|
-
|
-1.74
x
|
-0.7
x
|
-1.45
x
|
FCF Yield
|
-
|
-46.4%
|
-23.5%
|
-12.5%
|
-
|
-57.3%
|
-144%
|
-69.2%
|
Price to Book
|
-
|
-
|
-
|
3.05
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
2,119
|
3,908
|
21,722
|
40,248
|
52,586
|
63,822
|
-
|
-
|
Reference price
2 |
7.199
|
16.45
|
19.77
|
29.21
|
21.78
|
12.11
|
12.11
|
12.11
|
Announcement Date
|
3/11/20
|
3/26/21
|
3/10/22
|
3/8/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
4.461
|
1.05
|
2.963
|
1.772
|
0.314
|
0.3704
|
0.33
|
127.3
|
EBITDA
1 |
-
|
-
|
-65.14
|
-134
|
-186.8
|
-194.9
|
-244.7
|
-261.9
|
EBIT
1 |
-41.98
|
-110.4
|
-79.73
|
-134.3
|
-254.4
|
-253.6
|
-289.4
|
-297.1
|
Operating Margin
|
-941.02%
|
-10,512.38%
|
-2,690.79%
|
-7,579.23%
|
-81,035.03%
|
-68,467.03%
|
-87,686.5%
|
-233.36%
|
Earnings before Tax (EBT)
1 |
-41.87
|
-110.7
|
-79.41
|
-129.9
|
-237.7
|
-235.3
|
-266.6
|
-168.8
|
Net income
1 |
-41.87
|
-110.7
|
-79.41
|
-129.9
|
-237.7
|
-229.9
|
-265.9
|
-195.3
|
Net margin
|
-938.65%
|
-10,544.29%
|
-2,680.16%
|
-7,329.23%
|
-75,711.46%
|
-62,058.8%
|
-80,580.51%
|
-153.36%
|
EPS
2 |
-20.10
|
-31.13
|
-6.680
|
-4.050
|
-5.310
|
-3.707
|
-3.921
|
-2.797
|
Free Cash Flow
1 |
-
|
-29.82
|
-54.58
|
-94.64
|
-
|
-178
|
-212
|
-236
|
FCF margin
|
-
|
-2,840.1%
|
-1,842.09%
|
-5,340.58%
|
-
|
-48,058.75%
|
-64,242.42%
|
-185.36%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/26/21
|
3/10/22
|
3/8/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.214
|
0.216
|
0.256
|
1.195
|
0.105
|
0.098
|
0.072
|
0.072
|
0.072
|
0.072
|
0.0917
|
0.0898
|
0.1225
|
0.124
|
0.124
|
EBITDA
1 |
-25.56
|
-21.19
|
-24.62
|
-24.84
|
-48.97
|
-57.15
|
-46.84
|
-51.09
|
-45.28
|
-43.06
|
-46.85
|
-50.87
|
-53.99
|
-
|
-
|
EBIT
1 |
-29.08
|
-25.89
|
-29.56
|
-29.78
|
-49.07
|
-72.47
|
-59.28
|
-51.22
|
-71.48
|
-55.9
|
-62.97
|
-65.41
|
-69.38
|
-74.5
|
-77
|
Operating Margin
|
-13,589.25%
|
-11,985.65%
|
-11,548.44%
|
-2,492.47%
|
-46,729.52%
|
-73,952.04%
|
-82,326.39%
|
-71,144.44%
|
-99,276.39%
|
-77,634.72%
|
-68,680.23%
|
-72,863.87%
|
-56,615.72%
|
-60,080.65%
|
-62,096.77%
|
Earnings before Tax (EBT)
1 |
-28.95
|
-25.69
|
-29.49
|
-28.9
|
-45.78
|
-68.15
|
-55.06
|
-47.66
|
-66.86
|
-48.54
|
-58.98
|
-61.82
|
-66
|
-67.73
|
-68.22
|
Net income
1 |
-28.95
|
-25.69
|
-29.49
|
-28.9
|
-45.78
|
-68.15
|
-55.06
|
-47.66
|
-66.86
|
-48.54
|
-57.18
|
-61.12
|
-63.6
|
-67.73
|
-68.22
|
Net margin
|
-13,526.17%
|
-11,894.91%
|
-11,519.92%
|
-2,418.83%
|
-43,604.76%
|
-69,541.84%
|
-76,476.39%
|
-66,194.44%
|
-92,861.11%
|
-67,419.44%
|
-62,362.31%
|
-68,085.94%
|
-51,899.79%
|
-54,623.79%
|
-55,018.55%
|
EPS
2 |
-1.320
|
-0.9800
|
-1.060
|
-0.8600
|
-1.130
|
-1.610
|
-1.270
|
-1.090
|
-1.350
|
-0.7900
|
-0.9036
|
-0.9621
|
-0.9857
|
-0.9675
|
-0.9825
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/22
|
5/12/22
|
8/15/22
|
11/14/22
|
3/8/23
|
5/10/23
|
8/8/23
|
11/13/23
|
2/27/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
22.5
|
-
|
197
|
420
|
457
|
462
|
625
|
432
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-29.8
|
-54.6
|
-94.6
|
-
|
-178
|
-212
|
-236
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
9.560
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-2.920
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.04
|
-
|
0.8
|
0.9
|
1.25
|
1.75
|
2
|
Capex / Sales
|
-
|
4%
|
-
|
44.98%
|
285.99%
|
337.49%
|
530.3%
|
1.57%
|
Announcement Date
|
3/11/20
|
3/26/21
|
3/10/22
|
3/8/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
12.11
USD Average target price
36.5
USD Spread / Average Target +201.40% Consensus |
1st Jan change
|
Capi.
|
---|
| -44.40% | 773M | | +67.53% | 63.85B | | -0.77% | 41.83B | | +45.66% | 40.65B | | -10.72% | 27.12B | | +13.30% | 26.52B | | -22.79% | 18.69B | | +4.70% | 12.73B | | +24.10% | 12.11B | | +27.41% | 12.07B |
Other Biotechnology & Medical Research
|